Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.65 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.65 |
| ▸ | CYP4Z1 | Q86W10 | 3/20 | 0.59 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.59 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27937264 | 0.95 | CYP4F2 (0.63) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL4889211 | 0.89 | CYP4F2 (0.80) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL765847 | 0.88 | CYP4F2 (0.62) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL10289874 | 0.88 | CYP4F2 (0.62) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL765000 | 0.88 | CYP4F2 (0.62) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL5050631 | 0.86 | CYP4F2 (0.60) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL5545806 | 0.86 | CYP4F2 (0.60) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL9671800 | 0.86 | CYP4Z1 (0.65) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL23959915 | 0.85 | CYP4F2 (0.58) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL5871481 | 0.85 | CYP4F2 (0.58) | CYP4F2CYP4A11CYP4Z1CYP4F11CYP4F12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968192-B2 | Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis | LEXICON PHARMACEUTICALS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200255394-A1 | CRYSTALLINE SOLID FORMS OF N-(1-((2-(DIMETHYLAMINO)ETHYL)AMINO)-2-METHYL-1-OXOPROPAN-2-YL)-4-(4-(2-METHYL-5-((2S,3R,4R,5S,6R)-3,4,5-TRIHYDROXY-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-2-YL)BENZYL)PHENYL)BUTANAMIDE AND METHODS OF THEIR SYNTHESIS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2020-08-13 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255394-A1 | CRYSTALLINE SOLID FORMS OF N-(1-((2-(DIMETHYLAMINO)ETHYL)AMINO)-2-METHYL-1-OXOPROPAN-2-YL)-4-(4-(2-METHYL-5-((2S,3R,4R,5S,6R)-3,4,5-TRIHYDROXY-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-2-YL)BENZYL)PHENYL)BUTANAMIDE AND METHODS OF THEIR SYNTHESIS | HTR3C, KDM4E, BCHE | CYP4F2 1192/4885CYP4A11 1511/4885CYP4Z1 1476/4885 |
| US-10968192-B2 | Crystalline solid forms of N-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis | HTR3C, KDM4E, BCHE | CYP4F2 1192/4885CYP4A11 1511/4885CYP4Z1 1476/4885 |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | CYP4F2 116/4885CYP4A11 50/4885CYP4Z1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.